Brain insulin signaling is increased in insulin-resistant states and decreases in FOXOs and PGC-1a and increases in Aβ1-40/42 and phospho-tau may abet Alzheimer development

Diabetes

Volumn 65, Issue 7, 2016, Pages 1892-1903

  Sajan, Mini ^a,b   Hansen, Barbara ^b   Ivey, Robert ^a   Sajan, Joshua ^a   Ari, Csilla ^b   Song, Shijie ^a   Braun, Ursula ^c   Leitges, Michael ^c   Farese Higgs, Margaret ^a   Farese, Robert V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; PROTEIN KINASE C; TAU PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; AMYLOID BETA PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; FOXO4 PROTEIN, MOUSE; PEPTIDE FRAGMENT; PKC-3 PROTEIN; PPARGC1A PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN FUNCTION; CONFERENCE PAPER; CONTROLLED STUDY; DIET INDUCED OBESITY; FEMALE; GLUCOSE TRANSPORT; HAPLORHINI; HIPPOCAMPUS; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OB/OB MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; NERVE CELL; OBESITY; PHOSPHORYLATION; PHYSIOLOGY; RHESUS MONKEY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FEMALE; FORKHEAD BOX PROTEIN O1; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; INSULIN; INSULIN RESISTANCE; MACACA MULATTA; MALE; MICE; NEURONS; OBESITY; PEPTIDE FRAGMENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84975862605     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1428     Document Type: Conference Paper

References (53)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
2. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia 2005;48:2460-2469
3. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MMB Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39:1392-1397
4. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-481
5. Frölich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) 1998;105:423-438
6. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm (Vienna) 2002;109:991-1002
7. Sajan MP, Standaert ML, Miura A, Kahn CR, Farese RV. Tissue-specific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver, and adipocytes of insulin receptor substrate-1 knockout mice. Mol Endocrinol 2004;18:2513-2521
8. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18:902-904
9. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007;4: 147-152
10. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012;9:35-66
11. De Felice FG. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 2013;123:531-539
12. Kahn RC, Suzuki R. Insulin action in the brain and the pathogenesis of Alzheimer's disease. In Diabetes, Insulin and Alzheimer's Disease. Craft S, Ed. New York, Springer-Verlag, 2010, p. 1-20
13. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001;20:27-39
14. Wang J-Z, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007; 25:59-68
15. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38
16. Sajan MP, Acevedo-Duncan ME, Standaert ML, Ivey RA III, Lee MC, Farese RV. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/Propeller/FYVE scaffold and is selectively inhibited atypical PKC in early phases of diet-induced obesity. Diabetes 2014;63:2690-2701
17. Sajan MP, Ivey RA III, Lee MC, Farese RV. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation. J Lipid Res 2015;56:70-80
18. Sajan MP, Farese RV. Insulin signalling in hepatocytes of type 2 diabetic humans. Excessive expression and activity of PKC-i and dependent processes and reversal by PKC-i inhibitors. Diabetologia 2012;55:1446-1457
19. Sajan MP, Ivey RA III, Farese RV. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1a in livers of obese and type 2 diabetic humans. Metabolism 2015;64:1454-1465
20. Farese RV, Sajan MP, Yang H, et al. Muscle-specific knockout of PKC-l impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007;117:2289-2301
21. Sajan MP, Nimal S, Mastorides S, et al. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-i. Metabolism 2012;61:459-469
22. Hansen BC Investigation and treatment of type 2 diabetes in nonhuman primates. Methods Mol Biol 2012;933:177-185
23. Lee HW, Muniyappa R, Yan X, et al. Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic glucose clamps in rhesus monkeys. Endocrinology 2011;152:414-423
24. Sacktor TC PKMzeta, LTP maintenance, and the dynamic molecular biology of memory storage. Prog Brain Res 2008;169:27-40
25. Lee AM, Kanter BR, Wang D, et al. Prkcz null mice show normal learning and memory. Nature 2013;493:416-419
26. Volk LJ, Bachman JL, Johnson R, Yu Y, Huganir RL. PKM-z is not required for hippocampal synaptic plasticity, learning and memory. Nature 2013;493: 420-423
27. Freude S, Plum L, Schnitker J, et al. Perpheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005;54:3343-3348
28. Beeson M, Sajan MP, Dizon M, et al. Activation of protein kinase C-z by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 2003;52:1926-1934
29. White MF IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes Metab 2014;16(Suppl. 1):4-15
30. Polter A, Yang S, Zmijewska AA, et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009;65: 150-159
31. Ausserlechner MJ, Haugenbuchner J, Fuchs S, Geiger K, Obexer P. FOXO transcription factors as potential therapeutic targets in neuroblastoma. In Neuroblastoma: Present and Future. Shimada H, Ed. Rijecha, Croatia, InTech, 2012
32. Salih DAM, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 2008;20:126-136
33. Renault VM, Rafalski VA, Morgan AA, et al. FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 2009;5:527-539
34. Paik J-H, Ding Z, Narurkar R, et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 2009;5: 540-553
35. Salih DAM, Rashid AJ, Colas D, et al. FoxO6 regulates memory consolidation and synaptic function. Genes Dev 2012;26:2780-2801
36. Stöhr O, Schilbach K, Moll L, et al. Insulin receptor signaling mediates APP processing and b-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. Age (Dordr) 2013;35:83-101
37. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006;313:1604-1610
38. Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 2005;93: 105-117
39. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 2004;15:955-959
40. Pei J-J, Khatoon S, An W-L, et al. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 2003;105:381-392
41. Zemva J, Schilbach K, Stöhr O, et al. Central FoxO3a and FoxO6 expression is down-regulated in obesity induced diabetes but not in aging. Exp Clin Endocrinol Diabetes 2012;120:340-350
42. Anekonda TS Resveratrol - a boon for treating Alzheimer's disease? Brain Res Brain Res Rev 2006;52:316-326
43. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169-3179
44. Diatoku H, Sakamaki J, Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011; 1813:1954-1960
45. MacPherson REK, Baumeister P, Peppler WT, Wright DC, Little JP. Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice. J Appl Physiol (1985) 2015;119:1097-1104
46. Qin W, Zhao W, Ho L, et al. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann NY Acad Sci 2008;1147:335-347
47. Nuzzo D, Picone P, Baldassano S, et al. Insulin resistance as a common molecular denominator linking obesity to Alzheimer's disease. Curr Alzheimer Res 2015;12:723-735
48. Pedersen WA, Flynn ER. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2004;17:500-506
49. Kohjima M, Sun Y, Chan L. Increased food intake leads to obesity and insulin resistance in the Tg2576 Alzheimer's disease mouse model. Endocrinology 2010;151:1532-1540
50. Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009;66: 352-361
51. Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 2012; 120:419-429
52. Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-g coactivator 1a regulated b-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013;34:1581-1588
53. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009;150:5294-5301